Latest news

Thumbnail image for MSD’s Prevymis approved for CMV prevention

MSD’s Prevymis approved for CMV prevention

MSD’s Prevymis has been green-lighted in the US to prevent cytomegalovirus infection and disease in at-risk adults who have received an allogeneic hematopoietic stem cell transplant (HSCT).

13th November 2017

Thumbnail image for Bayer, Janssen’s Xarelto cuts risk of amputation, death

Bayer, Janssen’s Xarelto cuts risk of amputation, death

Two new analyses of data from the COMPASS trial show that Bayer and Janssen’s blood thinner Xarelto significant cut the amputation rate for patients with peripheral artery disease and also a 23 percent reduction in deaths in patients with coronary artery disease.

13th November 2017

Thumbnail image for Ten new medicines leap towards EU approval

Ten new medicines leap towards EU approval

The European Medicines Agency’s Committee for Medicinal Products for Human Use has put 10 medicines forward for approval in the region, including new options for multiple sclerosis, eosinophilic esophagitis and eosinophilic asthma.

13th November 2017

Thumbnail image for NPL, Imperial College London launch new virtual lab

NPL, Imperial College London launch new virtual lab

NPL and Imperial College London have unveiled a new £7 million virtual lab to help the UK’s synthetic biology industry enhance the manufacturing and adoption of new drugs, therapies and other products.

10th November 2017

Thumbnail image for NICE backs Merck’s Mavenclad for MS

NICE backs Merck’s Mavenclad for MS

Merck’s Mavenclad is being backed by the National Institute for Health and Clinical Excellence as an option for treating highly active multiple sclerosis in adults on the NHS.

10th November 2017

Thumbnail image for Sanofi buys rights to Principia’s BTK inhibitor

Sanofi buys rights to Principia’s BTK inhibitor

Sanofi has bought itself rights to Principia BioPharma’s experimental tyrosine kinase (BTK) inhibitor PRN2246, in a deal potentially worth more than $800 million to the latter firm.

10th November 2017

Thumbnail image for AZ books 3 percent sales drop for Q3

AZ books 3 percent sales drop for Q3

AstraZeneca has booked another sales decline for the third quarter but says the impact of generic competition is starting to wane.

9th November 2017

Previous  --   10 11 12 13 14 15 16 17 18 19   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download